Compare McKesson Corporation (MCK) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs VNET Group Inc — how do they compare? McKesson Corporation trades at $824.27 (market cap $97.35B), while VNET Group Inc trades at $7.77 (market cap $2.19B). The key difference: McKesson Corporation is far larger — about 44.5× VNET Group Inc's market cap, and McKesson Corporation pays a 0.39% dividend while VNET Group Inc pays none. Which is the better fit depends on your goals.
| MCK | VNET | |
|---|---|---|
Market Cap | $97.35B | $2.19B |
Sector | Health | Technology |
52-Week High | $995.69 | $14.03 |
52-Week Low | $659.01 | $7.34 |
Enterprise Value | $101.98B | $5.32B |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
VNET Group trades at $7.675, up 3.86% today, but technical indicators signal a bearish trend with moving averages unanimously negative. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investments in AI and data center capacity, alongside a class action settlement announcement.
The outlook is mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and bearish technicals pose risks. Investment opportunity hinges on execution of growth initiatives in AI-driven demand, while key risks include profitability challenges and competitive pressures in the data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
